BUZZ-Suzhou Ribo jumps on first milestone achievement from Madrigal tie-up

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL

0.00

** Suzhou Ribo Life Science 6938.HK shares jump 10.7% to HK$51.9, their highest level since June 9

** China-based oligonucleotide developer on course for biggest one-day pct gain since April 1

** Co says first candidate drug nomination milestone achieved in siRNA partnership with Madrigal Pharmaceuticals Inc MDGL.O to advance cutting-edge RNA therapeutics for liver diseases, with focus on metabolic dysfunction-associated steatohepatitis (MASH)

** Company and Madrigal aim to develop promising siRNA drug by utilizing the company’s liver-targeting RiboGalSTAR platform, to deliver more targeted and effective treatments for MASH patients - co

** MASH is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality

** Since January 9 debut, Suzhou Ribo down 13.7% from offer price


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.